Abstract: 17-methylene-4-azasteroid compounds of formula I: wherein R20 denotes fluoro, chloro or bromo R20a denotes hydrogen, R10 and R4 each denote a hydrogen atom or a methyl group, and R1 and R2 each denote a hydrogen atom or together denote an additional bond, are useful for treating diseases or conditions caused by excessive androgen levels, such as acne, prostate diseases, alopecia and hirsutism, as well as gynecological conditions. Methods of synthesizing the new 17-methylene-4-azasteroid compounds are described.

Abstract: This invention describes the new, nonsteroidal gestagens of general formula I 1

Abstract: This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar1, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gestagen receptor. They can be used alone or in combination with estrogens in contraceptive preparations. In addition, they can be used for treating endometriosis. Together with estrogens, they can also be used in preparations for treating gynecological disorders, for treating premenstrual symptoms and for substitution therapy. Based on the androgenic action, they can also be used for male birth control, male HRT and hormone therapy and for treating andrological disease agents.

Abstract: This invention describes the new, nonsteroidal gestagens of general formula I 1

Abstract: This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gestagen receptor. They can be used alone or in combination with estrogens in contraceptive preparations. In addition, they can be used for treating endometriosis. Together with estrogens, they can also be used in preparations for treating gynecological disorders, for treating premenstrual symptoms and for substitution therapy. Based on the androgenic action, they can also be used for male birth control, male HRT and hormone therapy and for treating andrological disease agents.

Abstract: This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gestagen receptor. They can be used alone or in combination with estrogens in contraceptive preparations. In addition, they can be used for treating endometriosis. Together with estrogens, they can also be used in preparations for treating gynecological disorders, for treating premenstrual symptoms and for substitution therapy. Based on the androgenic action, they can also be used for male birth control, male HRT and hormone therapy and for treating andrological disease agents.

Abstract: The disclosure relates to novel dopamine derivatives of general Formula I ##STR1## wherein A is a substituted phenyl residue of the structure ##STR2## wherein R.sup.1 and R.sup.2, being identical or different, mean hydrogen, C.sub.1-15 -alkyl and allyl,D is ##STR3## R.sub.4 is hydrogen, C.sub.1 -C.sub.4 -alkyl, CF.sub.3, NH.sub.2 E is ##STR4## X is OH, NH.sub.2, ##STR5## and NH--SO.sub.2 --CF.sub.3, if Y=OH, Y is OH, NH.sub.2, ##STR6## NH--SO.sub.2 --CF.sub.3 and NH--SO.sub.2 --CH.sub.3, if X=OH, but wherein X and Y do not simultaneously mean OH, with R.sup.3 being C.sub.1-4 -alkyl, andZ is H or OH, and, if Z means the hydroxy group, the residue A can also be present in the tautomeric basic form,and their acid addition salts, their preparation, and use as medicinal agents having antihypertensive activity.